Searchable abstracts of presentations at key conferences in endocrinology

ea0011p191 | Clinical practise and governance | ECE2006

Concordance between GH determination and IGF-I in acromegaly using two IGF-I methods

Hepburn S , Chambers SM , Gilbert JA , McGregor AM , Miell JP , Aylwin SJB

Introduction and aims: Following treatment for acromegaly, both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels are predictive of mortality. These data are derived from studies of either a single GH or the mean circadian GH, with a threshold of 2 mcg/l. However, consensus target criteria (Giustina et al. 2000) require: a nadir GH of <1 mcg/l on OGTT and IGF-I within the age/sex-adjusted normal range. We aimed to determine the degree to which norm...

ea0011oc57 | ThyroidOC57 British Thyroid Association Award | ECE2006

Treatment of experimental hyperthyroid Graves’ disease with decoy TNF-family ligand receptors, suggests an essential role for BAFF in production of thyroid stimulating antibodies

Gilbert JA , Kalled SL , Moorhead J , Hess D , Rennert P , Li Z , Khan Z , Banga J-P

Introduction and Aims: GravesÂ’ disease (GD) is mediated by thyroid stimulating antibodies (TSAbs) to the TSH receptor (TSHR). Treatments for GD have remained unchanged for more than 40 years with less than 50% of patients achieving long term remission with medical therapy. Experimental animal models have been described which facilitate understanding of disease mechanisms and permit studies of novel immunotherapeutic interventions. However studies aiming to perturb the Th1...